Fildena 25 mg can be very effective in treating ED, but it's not right for everybody. That's because Fildena Purple was the first oral pill to treat ED. It was approved by the U.S.

Fildena is essentially the brand name of the drug Sildenafil. Fildena cut in half the formation of polyps, an abnormal and often asymptomatic clump of cells on the lining of the intestines that may become cancer, says Dr. Darren D. Browning, cancer researcher at the Georgia Cancer Center and Department of Biochemistry and Molecular Biology at the Medical College of Georgia at Augusta University. Fildena can also have more serious side effects. The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold see Warnings and Precautions (5.6) , Drug Interactions (7.4) , and Clinical Pharmacology (12.3)

The maximum dose of sildenafil recommended by the manufacturer is 100 mg. A study was designed to prospectively review a group of patients with chronic ED, unresponsive to sildenafil 100 mg, who were treated in a home setting with doses of sildenafil in excess of the recommended maximum dose (150 mg and 200 mg). Erections of sufficient rigidity and duration for satisfactory sexual intercourse occurred in 13 patients (24.1%) at a median maximal dose of 200 mg. Four patients (7.4%) required 150 mg and comprised 2 patients with psychogenic ED and 2 patients with arteriogenic ED. The remaining 9 patients (16.7%) required 200 mg and comprised 2 patients with psychogenic ED, 3 patients with arteriogenic ED, 2 patients with cavernosal veno-occlusive dysfunction and 2 patients with post radical prostatectomy ED. Nine of the 13 patients (69%) who responded chose to continue therapy with sildenafil. Eight of these 34 patients (23.5%) reported 1 adverse effect, 14 patients (41.2%) reported 2, 25 patients (29.4%) reported 3 and 2 patients (5.9%) reported 4 or more side effects
12 Of the treatment options currently available, sildenafil most closely fulfils these criteria. The majority of the 30-35% of ED sufferers who fail to respond to the maximum recommended dose of sildenafil (100 mg), chose ICI therapy as second line therapy. This study demonstrates that administration of sildenafil at doses of 150-200 mg results in sufficient rigidity to achieve vaginal intromission and complete satisfactory sexual intercourse in 24.1% of ED sufferers who had previously failed a trial of sildenafil 100 mg. This is contrary to the manufacturer sponsored pre-marketing studies, where the erectile response to a dose of 200 mg was not differentiable from 100 mg. 17 In this study, the response to sildenafil was independent of patient age and duration of ED but was highly dependent on etiology of ED. Rigidity sufficient for satisfactory sexual intercourse was reported by 80% of patients with psychogenic ED but only 18.4% of patients with organic ED. As has been reported previously, patients with CVOD appear less likely to respond to sildenafil as is the case with ICI treatment.
Lowentritt et al reported improved erections in 53% and improved capacity for sexual intercourse in 40% of patients taking sildenafil after nerve sparing RRP which was dependent on patient age, pathological stage and degree of nerve sparing surgical technique.

For details about Viagra Purple internet page: this site.